Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : BRS1RPBDR005
Share Class Description:
BSP:S1RP34: BRDRCompare
Compare
Traded in other countries / regions
SRPT.USAAB3A.GermanyS1RP34.Brazil0L35.UK IPO Date
2020-10-13Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.01 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 1.44 | |||||
| Debt-to-EBITDA | 14.41 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.68 | |||||
| Beneish M-Score | -1.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.8 | |||||
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 30.8 | |||||
| 3-Year Book Growth Rate | -1.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 61.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 93.22 | |||||
| 9-Day RSI | 85.18 | |||||
| 14-Day RSI | 78.9 | |||||
| 6-1 Month Momentum % | 8.2 | |||||
| 12-1 Month Momentum % | -7.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.05 | |||||
| Quick Ratio | 3.44 | |||||
| Cash Ratio | 2.28 | |||||
| Days Inventory | 602.87 | |||||
| Days Sales Outstanding | 81.08 | |||||
| Days Payable | 246.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.7 | |||||
| Shareholder Yield % | 0.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.18 | |||||
| Operating Margin % | -6.76 | |||||
| Net Margin % | 1.2 | |||||
| FCF Margin % | -46.69 | |||||
| ROE % | 2.09 | |||||
| ROA % | 0.54 | |||||
| ROIC % | -4.09 | |||||
| ROC (Joel Greenblatt) % | 9.53 | |||||
| ROCE % | 2.07 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 340.28 | |||||
| Forward PE Ratio | 43.29 | |||||
| PE Ratio without NRI | 178.86 | |||||
| PEG Ratio | 57.7 | |||||
| PS Ratio | 9.28 | |||||
| PB Ratio | 13.38 | |||||
| Price-to-Tangible-Book | 13.77 | |||||
| EV-to-EBIT | 238.43 | |||||
| EV-to-Forward-EBIT | 25.48 | |||||
| EV-to-EBITDA | 134.25 | |||||
| EV-to-Forward-EBITDA | 23.12 | |||||
| EV-to-Revenue | 9.16 | |||||
| EV-to-Forward-Revenue | 6.99 | |||||
| EV-to-FCF | -19.66 | |||||
| Price-to-DCF (Earnings Based) | 16.56 | |||||
| Price-to-Median-PS-Value | 0.33 | |||||
| Price-to-Graham-Number | 10.46 | |||||
| Price-to-Net-Current-Asset-Value | 64.45 | |||||
| Earnings Yield (Greenblatt) % | 0.42 | |||||
| FCF Yield % | -5.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 6,909.832 | ||
| EPS (TTM) (R$) | 0.098 | ||
| Beta | -0.85 | ||
| Volatility % | 54.47 | ||
| 14-Day RSI | 78.9 | ||
| 14-Day ATR (R$) | 0.577375 | ||
| 20-Day SMA (R$) | 32.456 | ||
| 12-1 Month Momentum % | -7.87 | ||
| 52-Week Range (R$) | 18.89 - 38.1 | ||
| Shares Outstanding (Mil) | 1,890.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sarepta Therapeutics Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(BSP:S1RP34)'s stock price today?
The current price of BSP:S1RP34 is R$36.09. The 52 week high of BSP:S1RP34 is R$38.10 and 52 week low is R$18.89.
When is next earnings date of Sarepta Therapeutics Inc(BSP:S1RP34)?
The next earnings date of Sarepta Therapeutics Inc(BSP:S1RP34) is 2024-08-02 Est..
Does Sarepta Therapeutics Inc(BSP:S1RP34) pay dividends? If so, how much?
Sarepta Therapeutics Inc(BSP:S1RP34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers